Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07098806 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
A Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07098806 is a Phase 1 study of Leptomeningeal Metastasis that is actively recruiting participants, run by Plus Therapeutics. The registered enrollment target is 24 participants, below the 57-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07098806, a Phase 1 study of Leptomeningeal Metastasis, is actively recruiting participants, sponsored by Plus Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Conditions Studied
Interventions
- DRUG 186RNL
Study Locations (1)
Texas
- The Cancer Therapy and Research Center at UTHSCSA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2031-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07098806
The ClinicalTrials.gov registry entry for NCT07098806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 57-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (58% lower). The listed sponsor is Plus Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leptomeningeal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which 186RNL is the first listed.
NCT07098806 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07098806 about?
NCT07098806 is a clinical study titled "Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases ...
What is the current status of trial NCT07098806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-07-02. Estimated completion is 2031-10-02.
What conditions does trial NCT07098806 study?
This clinical trial studies the following conditions: Leptomeningeal Metastasis.
What interventions are being tested in trial NCT07098806?
The interventions under investigation include: 186RNL (DRUG).
Who is sponsoring clinical trial NCT07098806?
This trial is sponsored by Plus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07098806 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
-
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.